US3384541A - Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants - Google Patents

Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants Download PDF

Info

Publication number
US3384541A
US3384541A US40723164A US3384541A US 3384541 A US3384541 A US 3384541A US 40723164 A US40723164 A US 40723164A US 3384541 A US3384541 A US 3384541A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
example
foam
vehicle
propylene glycol
spermicidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
William G Clark
Original Assignee
William G. Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; MISCELLANEOUS COMPOSITIONS; MISCELLANEOUS APPLICATIONS OF MATERIALS
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/30Materials not provided for elsewhere for aerosols
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/957Vapor emmitting composition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/967Vaginal

Description

United States Patent 3,384,541 SPERMICIDAL VAGINAL PHARMACEUTICAL CONCENTRATE FOR PRODUCENG NON- AQUEOUS FOAM WITH AEROSOL PROPEL- LANTS William G. Clark, 1142 Las Pulgas Road, Pacific Palisades, Calif. 90272 No Drawing. Filed Oct. 28, 1964, Ser. No. 407,231 1 Claim. (Cl. 167-58) ABSTRACT OF THE DISCLOSURE The invention provides a new composition of matter comprising a major proportion of propylene glycol in a minor proportion of an ethoxylated tallow alcohol, the composition being adapted to incorporation in foam-producing assemblies.

This invention relates to a new and useful non-aqueous foam-producing pharmaceutical substance, and more particularly to such a substance adapted for use as a medicant in a self-propelled dispenser using fluorinated hydrocarbons or other aerosol propellants.

There is a need for a simple, easily used single-dose contraceptive which can be applied as an aerosol foam into the vaginal canal. There has also been a need for a pharmaceutical vehicle for medicants adapted to be injected into human body cavities that can be used either with or without water, depending upon the stability of the ingredients to be incorporated into the preparation. Thus, it is desirable to have a single base that can be used with various enzymes, antibiotics, and medicinal agents, with or without spermicidal agents.

Accordingly, it is a primary object of the present invention to provide a newand useful non-aqueous foamproducing vehicle.

Another object of the invention is to provide a vehicle of the type described in combination with spermicidal substances.

Another object of the present invention is to provide a foam-producing vehicle that can be used either with or without water and various enzymes, antibiotics, and spermicidal agents.

Yet another object .of the present invention is to provide a new and useful non-aqueous foam-producing vehicle which contains ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, Wetting agent, and viscosity builder.

A further object of the present invention is to provide a vehicle of the type described which is also spermicidal.

A still further object of the present invention is to provide a vehicle of the type described which is especially suited for use in and in combination with aerosol type applicators for injecting medicants into human body cavities.

A medicinal application of this type is shown and claimed in copending application Ser. No. 407,170, filed Oct. 28, 1964, by the instant inventor, now abandoned.

The non-aqueous foam-producing pharmaceutical substance of the present invention includes a vehicle containing ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, wetting agent, and viscosity builder. The

3,384,541 Patented May 21, 1968 "ice ethoxylated alcohol is a condensate of pressure-hydrogenated tallow alcohol. The general formula is with R being a combination of CH (CH CH OH (stearyl alcohol 62%), CH (CH CH OH (cetyl alcohol 33%), and CH (CH CH OH (myristyl alcohol 5%) and the x ranging from three to eleven moles of ethylene oxide.

Propylene glycol U.S.P. may serve as a solvent, preservative, and emollient, and propylhydroxyparaben U.S.P. and methylhydroxyparaben U.S.P. are used as preservatives. In preparing the vehicle, grams of propylene glycol U.S.P'. are heated to approximately 50 degrees C. and 0.4 gram of methylhydroxyparaben plus 0.2 grain of propylhydroxyparaben are added and stirred. Two grams of ethoxylated tallow alcohol containing three moles of ethylene oxide, oil-soluble type, are heated to 50 degrees C., and combined with the propylene glycol preservative combination. Ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide may be used in this formula, depending upon the consistency of foam desired. The product is allowed to cool, and a sufficient amount of propylene glycol U.S.P. is added to make the product weigh 50 grams. Other glycols, as well as glycerol can be used in place of propylene glycol.

Spermicidal preparations are made from this vehicle, as described in the following examples, by dissolving the active ingredients in a sufiicient amount of propylene glycol U.S.P. to make 50 grams, and the resulting product is combined with 50 grams of the vehicle to make grams of spermicidal foam concentrate. In some cases, heat must be employed to effect solution. Heat labile substances must be added after cooling.

The non-ionic nature of the vehicle makes possible the addition of cationic or anionic substances without affecting the foam-producing and barrier action of the ingredients. Propylene glycol is an excellent solvent for many organic chemicals. Its solubility with water in all proportions makes possible the addition of aqueous solutions of spermicidal agents. This vehicle mixes quickly with seminal fluid and vaginal secretions, permitting rapid action of the active ingredients. Its surfactant action spreads the spermicide into all surfaces and crevices. The non-aqueous nature of the vehicle minimizes variations in action due to individual variations of moisture present. The viscous base and foam provide barrier action to passage of sperm through the cervix.

The vehicle itself is spermicidal as shown by the Sanderson-Cramer method of spermicidal evaluation. The vehicle, when diluted with two parts of buffered fructose solution, kills human sperm in twenty seconds. The buffered fructose solution contained three percent fructose, 0.24% anhydrous phosphate, 0.01% mono potassium phosphate, 0.2% sodium chloride, and distilled water (q.s.).

When diluted with an equal volume of propylene glycol U.S.P., the vehicle of the present invention produces a foam with propellants from an aerosol container of the types shown and described in said copending application. A partial emulsification results when the foam concentrate is shaken with fluorinated hydrocarbons or other aerosol propellants. When released in the manner described in said copending application, an excellent foam is produced. The ratio of vehicle to added propylene glycol can be altered to vary the foam consistency or to compensate for viscosities of added substances. Because of the insolubility of the ethoxylated tallow alcohols in water, the latter can be added to stiffen the foam where it does not affect the stability of added substances.

The formulation has been shown to be non-toxic to the mucosa of the human vagina and cervix. An amount in excess of that ordinarily used, namely grams of the liquid foam concentrate, was applied to the cervical mucosa of six oflice patients and examination made the next morning. No indications of inflammation were seen, even on repeated application.

The vehicle of the present invention is stable over long periods of time and maintains the stability of added ingredients which are unstable in aqueous vehicles of the prior art.

The following are typical examples of the non-aqueous foam-producing pharmaceutical substance of the present invention:

EXAMPLE 1 EXAMPLE 2 The product of Example 1 was prepared in the manner of Example 1 except that the ethoxylated tallow alcohol contained four moles of ethylene oxide.

EXAMPLE 3 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained five moles of ethylene oxide.

EXAMPLE 4 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained six moles of ethylene oxide.

EXAMPLE 5 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained seven moles of ethylene oxide.

EXAMPLE 6 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eight moles of ethylene oxide.

EXAMPLE 7 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained nine moles of ethylene oxide.

EXAMPLE 8 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained ten moles of ethylene oxide.

EXAMPLE 9 The produce of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eleven moles of ethylene oxide.

EXAMPLE 10 A product was prepared in accordance with each of the preceding examples except that, in each case, eighty grams 1 of glycerol USP were used in place of the propylene glycol.

EXAMPLE 11 Grams Aliphatic polyoxyethylene ether (100% active.

Made from commercial tridecyl alcohol and ethylene oxide to give material with an inverse cloud point of approximately 40-42 C. The material is made by standard ethoxylation technique) 5 The vehicle of Example 1 50 Propylene glycol q.s. ad 100 The aliphatic polyoxyethylene ether provides an excellent spermicide. Its non-ionic nature permits its combination with anionic or cationic agents without any change in spermicidal or antibiotic power. This composition produces an excellent foam when combined with propellants in aerosol containers. The ratio of propylene glycol to vehicle can be altered to produce varied consistency of foam.

EXAMPLE 12 Grams Aliphatic polyoxyethylene ether (100% active, de-

scribed in Example 11) 5 Lactic acid U.S.P. 0.5 Distilled water 10 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s. ad

Sufiicient acid has been added to this product to produce a pH of 4.0 which increases the spermicidal power because it produces a condition resembling the vaginal pH of 4.5. Water has been added to aid in the ionization of the acid because the effect of acids in spermicides depends upon the extent to which they ionize.

EXAMPLE 13 Grams Aliphatic polyoxyethylene ether (100% active, de-

scribed in Example 11) 5 Papain 1 Vehicle of Example 2 50 Propylene glycol U.S.P. q.s. ad 100 EXAMPLE 14 Grams Aliphatic polyoxyethylene ether (100 active, de-

scribed in Example 11) 5 Trypsin 1 Vehicle of Example 3 50 Propylene glycol U.S.P. q.s. ad 100 Other pancreatic enzymes that could be used in the foam concentrate include cathepsins and chymotrypsin.

EXAMPLE l5 Grams Aliphatic polyoxyethylene ether of Example 11 5 Desoxyribonucleases (a Dornase proteolytic enzyme) 1 Vehicle of Example 4 50 Propylene glycol U.S.P. q.s. ad 100 Bacterial protease from B. Subtz'lis 1 Vehicle of Example 5 50 Propylene glycol U.S.P. q.s. ad 100 Other proteases from microbiological sources included those from Pseudomonas, Clostridia, and fungi. Hyaluronidase also has been used. The proteolytic enzymes described in Examples 13 through 16 enhance the mucolytic action upon sperm as well as vaginal and cervical mucous, allowing the spermicide to reach the sperm better. The cleansing and anti-inflammatory, antibioticenhancing, fibrinolytic, mucolytic, and debriding properties of such enzymes is known. Thus, they can be used in vehicles of the present invention for intravaginal infestations such as vaginitis, leukorrhea, trichomonas, moniliasis, as well as for hygienic and prophylactic purposes by incorporating them alone or in combination with suitable antiseptics, germicides, antibiotics, and peptizing agents such as carbamide. Water has been omitted in Examples 13 through 16 to increase the stability of the enzymes and antibiotics. Stability studies have shown that enzymes retain over 50% of their proteolytic activity against standard substrates when left at room temperature for six months.

Propylene glycol U.S.P. q.s. ad 100 This combination was formulated for instances where a contraceptive is desired in combination with trichomonal or other antibiotic or where the latter is desired alone in an aerosol foam treatment. It is known that Tyrothricin and Chlortetracycline are more active protozoal agents than streptomycin, chloramphenicol, or penicillin. Tyrothricin possesses many advantages over other antibiotics for use in the vehicle of the present invention. It is odorless and has remarkable stability, being stable in aqueous solutions and propylene glycol for long periods even at summer temperatures. Its solution in propylene glycol may be autoclaved without significant loss of activity. Its solubility in propylene glycol and its compatibility with many organic and inorganic substances makes it uniquely useful with a spermicidal composition. Lactic acid has been added to this composition to maintain a healthier flora in the vagina. As is known, the treatment of trichomonas vaginalis is directed toward cleanliness and maintenance of acid pH in the vagina. Water has been added to the formula to aid in the ionization of the acid.

EXAMPLE l8 Grams Aliphatic polyoxyethylene ether of Example 11 5 Tyrothricin 0.5 Papain 1 Vehicle of Example 7 50 Propylene glycol q.s. ad 100 can be expected in vivo that do not show in this test because of the enhanced action of the added enzymes and acids. No appreciable difference in spermicidal action was noted with the addition of antibiotics in vitro.

EXAMPLE 19 Grams Aliphatic polyoxyethylene ether of Example 11 5 Hydrocortisone alcohol, micronized 1 Vehicle of Example 8 50 Propylene glycol q.s. ad

Hydrocortisone can be used along with the contraceptive when its anti-inflammatory action is desired. The relative insolubility and its high degree of activity of the alcohol form make it useful, especially where the systemic effects of the glucocorticoid are not desired.

EXAMPLE 20 Grams Aliphatic polyoxyethylene ether of Example 1 5 Hydrocortisone alcohol, micronized 1 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Glycerol q.s. ad 100 This formula combines the anti-inflammatory qualities of Hydrocortisone with the anti-pyogenic action of neomycin plus contraceptive.

EXAMPLE 21 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 Other sulfonamides may be used in place of the sulfanilamide or a combination of two or more may be used. This formula is useful in the post-operative care of the cervix and for secondary invasions of trichomonas vaginalis.

EXAMPLE 22 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s.d. ad 100 This formula can be used when the action of a sulfonamide along with an antibiotic is desired plus contraceptive. Another sulfonamide or sulfonamides may be used as well as antibiotics.

EXAMPLE 23 Grams Aliphatic polyoxyethylene ether of Example 11 5 Povidone iodine NND 1 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 The addition of the iodine compound aids in the treatment of non-specific vaginitis and Candida albicans, Monilia, and T richomonas vaginalis along with a contraceptive.

EXAMPLE 24 Examples were prepared in accordance with each of the thirteen preceding examples (ll-23) execept that in each case the aliphatic polyoxyethylene ether was omitted.

While the particular embodiments of the present invention herein described in detail are fully capable of attaining the objects and providing the advantages hereinbefore stated, it is to be understood that they are merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended to the specific embodiments herein described other than as defined in the appended claim.

I claim:

1. A spermicidal vaginal pharmaceutical concentrate for producing non-aqueous foam with aerosol propellants comprising:

80 grams of propylene glycol;

0.4 gram of methylhydroxyparaben;

0.2 gram of propylhydroxyparaben; I

2 grams of ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide of the oilsoluble type; said composition of matter being nonaqueous, thereby constituting a stable vehicle for proteolytic enzymes and antibiotics.

References Cited UNITED STATES PATENTS 2,854,377 9/1958 Elias 16758 2,943,979 7/1960 Elias 167-58 3,055,834 9/1962 Charle et a1. 25290 8 3,131,152 4/1964 Klausner 252-305 3,219,525 11/1965 Berkow 167-58 3,240,396 3/ 1966 Friedenberg 222-146 3,244,589 4/ 1966 Sunnen et a1 167-58 OTHER REFERENCES McCutcheon, John W.: D & E, 1963, Detergents and Emulsifiers, 1963, Annual pub., 1963, Morristown, N.J., pp.: cover, inside front cover, 31, 33, 45, 57, 58, 62, 63, 86, 87, 112, 116, 131, 135.

Federal Register 30 (228): 14639 Nov. 25, 1965, Dimethyl Sulfoxide (DMSO) Preparations, Termination of Clinical Testing and Investigational Use.

Ferm: Teratogenic Efiect of Dimethyl Sulphoxide, Lancet, I, 1966, pp. 208-209, Jan. 22, 1966.

LEWIS GOTTS, Primary Examiner.

SHEP K. ROSE, Examiner.

US3384541A 1964-10-28 1964-10-28 Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants Expired - Lifetime US3384541A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3384541A US3384541A (en) 1964-10-28 1964-10-28 Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3384541A US3384541A (en) 1964-10-28 1964-10-28 Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants

Publications (1)

Publication Number Publication Date
US3384541A true US3384541A (en) 1968-05-21

Family

ID=23611185

Family Applications (1)

Application Number Title Priority Date Filing Date
US3384541A Expired - Lifetime US3384541A (en) 1964-10-28 1964-10-28 Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants

Country Status (1)

Country Link
US (1) US3384541A (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819528A (en) * 1968-12-23 1974-06-25 Procter & Gamble Stabilized aqueous enzyme compositions
US3929985A (en) * 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4551148A (en) * 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
WO1987002576A1 (en) * 1985-10-31 1987-05-07 Kv Pharmaceutical Company Vaginal delivery systems
FR2677369A1 (en) * 1991-06-05 1992-12-11 Promotion Rech Innovation Tec Aerosol foam
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US5340836A (en) * 1991-02-19 1994-08-23 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
US5573765A (en) * 1991-02-19 1996-11-12 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
JP2002534377A (en) * 1999-01-08 2002-10-15 スリーエム イノベイティブ プロパティズ カンパニー Formulations and methods for treating mucosal associated conditions with an immune response regulator
EP1495758A2 (en) * 1999-01-08 2005-01-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005105090A1 (en) * 2004-05-04 2005-11-10 Aq+ Plc Compositions for progeny gender control
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20110045037A1 (en) * 2007-11-30 2011-02-24 Foamix Ltd. Foam containing benzoyl peroxide
US20110178162A1 (en) * 2005-10-14 2011-07-21 Medical University Of South Carolina Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2854377A (en) * 1955-09-22 1958-09-30 Nathaniel M Elias Effervescent compositions containing a surface active agent
US2943979A (en) * 1959-06-23 1960-07-05 Nathaniel M Elias Concentrated foam-producing spermicides
US3055834A (en) * 1958-04-14 1962-09-25 Oreal Anhydrous anion-active detergents in the form of aerosols
US3131152A (en) * 1960-06-13 1964-04-28 Allied Chem Foam producing formulations
US3219525A (en) * 1963-01-16 1965-11-23 Menlo Park Lab Inc Vaginal douche solution
US3240396A (en) * 1963-06-11 1966-03-15 Robert M Friedenberg Aerosol dispenser
US3244589A (en) * 1962-10-26 1966-04-05 Sunnen Alkyl phenoxy polyethoxy ether spermicidal aerosol

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2854377A (en) * 1955-09-22 1958-09-30 Nathaniel M Elias Effervescent compositions containing a surface active agent
US3055834A (en) * 1958-04-14 1962-09-25 Oreal Anhydrous anion-active detergents in the form of aerosols
US2943979A (en) * 1959-06-23 1960-07-05 Nathaniel M Elias Concentrated foam-producing spermicides
US3131152A (en) * 1960-06-13 1964-04-28 Allied Chem Foam producing formulations
US3244589A (en) * 1962-10-26 1966-04-05 Sunnen Alkyl phenoxy polyethoxy ether spermicidal aerosol
US3219525A (en) * 1963-01-16 1965-11-23 Menlo Park Lab Inc Vaginal douche solution
US3240396A (en) * 1963-06-11 1966-03-15 Robert M Friedenberg Aerosol dispenser

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819528A (en) * 1968-12-23 1974-06-25 Procter & Gamble Stabilized aqueous enzyme compositions
US3929985A (en) * 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4551148A (en) * 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
WO1987002576A1 (en) * 1985-10-31 1987-05-07 Kv Pharmaceutical Company Vaginal delivery systems
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
WO1998019545A1 (en) * 1991-02-19 1998-05-14 Reinhard Mark S Composition and method for the treatment of vaginal yeast infections
US5340836A (en) * 1991-02-19 1994-08-23 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
US5573765A (en) * 1991-02-19 1996-11-12 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
FR2677369A1 (en) * 1991-06-05 1992-12-11 Promotion Rech Innovation Tec Aerosol foam
JP2002534377A (en) * 1999-01-08 2002-10-15 スリーエム イノベイティブ プロパティズ カンパニー Formulations and methods for treating mucosal associated conditions with an immune response regulator
EP1495758A2 (en) * 1999-01-08 2005-01-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1495758A3 (en) * 1999-01-08 2005-04-13 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080177075A1 (en) * 2004-05-04 2008-07-24 Aq+Plc Stephen Mabbott Associates Compositions For Progeny Gender Control
GB2430371A (en) * 2004-05-04 2007-03-28 Aq & Plc Compositions for progeny gender control
WO2005105090A1 (en) * 2004-05-04 2005-11-10 Aq+ Plc Compositions for progeny gender control
US20110178162A1 (en) * 2005-10-14 2011-07-21 Medical University Of South Carolina Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20110045037A1 (en) * 2007-11-30 2011-02-24 Foamix Ltd. Foam containing benzoyl peroxide
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions

Similar Documents

Publication Publication Date Title
US3091569A (en) Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
US3422186A (en) Methods for the removal of cerumen and the methods for the treatment of ear disease
US3346451A (en) Concentrated liquid lactic acid douche preparation containing aromatics
US3729568A (en) Acne treatment
US5442053A (en) Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US4186113A (en) Low irritating detergent compositions
US5500416A (en) Percutaneous absorption promoting agent and dermatologic preparation containing the same
US4675184A (en) Pharmaceutical composition containing interferon in stable state
US3244589A (en) Alkyl phenoxy polyethoxy ether spermicidal aerosol
US4247547A (en) Tretinoin in a gel vehicle for acne treatment
US5840744A (en) Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4707362A (en) Sustained release composition
US5719194A (en) Prevention and treatment of topical viral infections with perfluoropolyethers or compositions thereof
US5712257A (en) Topically active compositions of mismatched dsRNAs
US4551456A (en) Ophthalmic use of norfloxacin and related antibiotics
US3867533A (en) Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US5519059A (en) Antifungal formulation
US6379685B1 (en) Acidic aqueous chlorite teat dip with improved emollient providing shelf life, sanitizing capacity and tissue protection
US3906108A (en) Stabilized tretinoin cream emulsion
US5306501A (en) Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
US20130189191A1 (en) Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof
US4919838A (en) Bar shampoo and skin soap
US3751562A (en) Medicated gelled oils
US4999342A (en) Long lasting contraceptive suppository composition and methods of use
US5219877A (en) Lauryl alcohol as skin penetration enhancer for topical imidazole agents